Australia's largest stock trading and investment forum Australia's #1 stock forum

NEURIZON THERAPEUTICS LIMITED

5.88%

16.0¢

Market Cap $78.76M

Healthcare Biotechnology

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company... Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients, while exploring NUZ-001’s potential for broader neurodegenerative applications.More

Corporate Spotlight

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease.
View the full Corporate Spotlight

NUZ ADVANCES NUZ-001 & GLOBAL LICENSING AGREEMENT

Latest Threads

Tag

Subject

Ann: Neurizon Secures Loan Against 2025 R&D Tax Rebate

04:14

28

5.5K

04:14

Last post coads

28

5.5K

Ann: Appendix 4C & Quarterly Update

30/07/25

13

2.7K

30/07/25

Last post coads

13

2.7K

Neurizon inks $1.5M loan against R&D Tax Rebate

30/07/25

0

207

30/07/25

Last post ASX Insights

0

207

Ann: Neurizon Submits Clinical Hold Complete Response to FDA

30/07/25

56

15K

30/07/25

Last post sarge22

56

15K

NUZ Charting Thread

2

29/07/25

67

18K

29/07/25

Last post Captain Goodvybes

67

18K

NUZ -- New Investor thread

31 32 33

26/07/25

1.9K

620K

26/07/25

Last post Quiltman

1.9K

620K

Attn KPAX and other Science People re 200+ hidden proteins that may drive Alzheimer’s

25/07/25

0

295

25/07/25

Last post Moreforme

0

295

Ann: Positive feedback from FDA on strategy to lift clinical hold

2

23/07/25

73

21K

23/07/25

Last post ThriftyClown

73

21K

NUZ Perplexity Assessments

2

21/07/25

63

17K

21/07/25

Last post Peeteepoo

63

17K

Ann: Neurizon Commences Initiatives to Lift Clinical Hold

2 3

18/07/25

153

44K

18/07/25

Last post Paralogical

153

44K

Ann: Neurizon Enters Global Licensing Agreement with Elanco

2 3

17/07/25

176

45K

17/07/25

Last post adreamer

176

45K

Pharmaust - Media & News

4 5 6

16/07/25

353

130K

16/07/25

Last post NZ Trader

353

130K

Ann: NUZ-001 Shows Promise in a Model of Huntington's Disease

2

13/07/25

76

23K

13/07/25

Last post Icebluedenim

76

23K

Pharmaust brand name required

09/07/25

41

9.8K

09/07/25

Last post Jakjazz

41

9.8K

Ann: Presentation Materials - Licensing Agreement Webinar

06/07/25

22

6.0K

06/07/25

Last post Cashtrain

22

6.0K

NUZ TOP HOLDERS MOVEMENT REPORT 30 JUNE 2025

03/07/25

4

1.3K

03/07/25

Last post Captain Goodvybes

4

1.3K

See All Discussions

Corporate Spotlight

ABOUT NEURIZON

Timeline

Appendix 4C & Quarterly Update
30 Jul 09:14	Share

Neurizon Secures Loan Against 2025 R&D Tax Rebate
30 Jul 09:10	Share

Neurizon Submits Clinical Hold Complete Response to FDA
25 Jul 09:22	Share

Positive feedback from FDA on strategy to lift clinical hold
10 Jul 09:15	Share

Presentation Materials - Licensing Agreement Webinar
02 Jul 12:20	Share

Invitation to Shareholder Webinar
02 Jul 08:58	Share

Neurizon Enters Global Licensing Agreement with Elanco
02 Jul 08:49	Share

Notification regarding unquoted securities - NUZ
26 Jun 17:57	Share

Neurizon develops liquid formulation of NUZ-001
26 Jun 09:24	Share

NUZ-001 Shows Significant Blood-Brain Barrier Penetration
20 Jun 09:32	Share

Release of Securities from Escrow
16 Jun 19:12	Share

NUZ-001 Shows Promise in a Model of Huntington's Disease
16 Jun 09:32	Share

Change of Registered Office and Principal Place of Business
02 Jun 09:45	Share

Neurizon to present at Annual ALS Drug Development Summit
14 May 16:54	Share

Neurizon to present Q3 FY2025 Results
06 May 12:48	Share

Last Patient Successfully Completes Treatment in OLE Study
05 May 09:23	Share

Appendix 4C & Quarterly Update
28 Apr 09:11	Share

Notice of Quarterly Shareholder Update Webinar
24 Apr 09:28	Share

Appointment of Chief Financial Officer
22 Apr 09:28	Share

Leadership team strengthened with strategic appointments
17 Apr 09:22	Share

NUZ-001 Promotes Survival in TDP-43 Challenged NSC-34 Cells
04 Apr 12:07	Share

NUZ-001 Shows Positive Results in Human 3D Brain Model
01 Apr 09:03	Share

NUZ-001 shows promising respiratory outcome
24 Mar 09:47	Share

Neurizon Commences Initiatives to Lift Clinical Hold
17 Mar 09:22	Share

Appendix 4D - Half-year Financial Report - 31 December 2024
17 Feb 14:28	Share

Neurizon to Present Latest Results and Key Updates
17 Feb 09:27	Share

FDA Guidance on NUZ-001 IND Application
17 Feb 09:14	Share

Notice of Company Update Webinar
11 Feb 14:29	Share

Change of Director's Interest Notices x3
07 Feb 09:58	Share

US Patent granted for NUZ-001
05 Feb 09:18	Share

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 16.0¢		Change -0.010(5.88%)		Mkt cap ! $78.76M

Open	High	Low	Value	Volume
17.0¢	17.0¢	16.0¢	$77.81K	468.1K

Buyers (Bids)

No.	Vol.	Price($)
4	171760	16.0¢

Sellers (Offers)

Price($)	Vol.	No.
17.0¢	115944	3

View Market Depth

No.	Vol.	Price($)
1	498	0.165
3	161760	0.160
5	156450	0.155
7	846288	0.150
1	260751	0.145

Price($)	Vol.	No.
0.160	499	1
0.170	115944	3
0.175	116776	3
0.180	168046	4
0.185	169014	4

Last trade - 15.02pm 30/07/2025 (20 minute delay)

NUZ (ASX) Chart